These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold. Giannini G; Battistuzzi G; Vesci L; Milazzo FM; De Paolis F; Barbarino M; Guglielmi MB; Carollo V; Gallo G; Artali R; Dallavalle S Bioorg Med Chem Lett; 2014 Jan; 24(2):462-6. PubMed ID: 24388690 [TBL] [Abstract][Full Text] [Related]
3. [Design, synthesis and biological evaluation of novel para-substituted 1-benzyl-quinazoline-2, 4 (1H, 3H)-diones as human PARP-1 inhibitors]. Yao HP; Zhu ZX; Ji M; Chen XG; Xu BL Yao Xue Xue Bao; 2014 Apr; 49(4):497-503. PubMed ID: 24974467 [TBL] [Abstract][Full Text] [Related]
4. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase. Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225 [TBL] [Abstract][Full Text] [Related]
5. Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. Menear KA; Adcock C; Alonso FC; Blackburn K; Copsey L; Drzewiecki J; Fundo A; Le Gall A; Gomez S; Javaid H; Lence CF; Martin NM; Mydlowski C; Smith GC Bioorg Med Chem Lett; 2008 Jul; 18(14):3942-5. PubMed ID: 18579376 [TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115 [TBL] [Abstract][Full Text] [Related]
7. Exploring the effect of PARP-1 flexibility in docking studies. Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306 [TBL] [Abstract][Full Text] [Related]
8. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors. Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of isoindoloisoquinolinone, pyroloisoquinolinone and benzoquinazolinone derivatives as poly(ADP-ribose) polymerase-1 inhibitors. Suyavaran A; Ramamurthy C; Mareeswaran R; Shanthi YV; Selvakumar J; Mangalaraj S; Kumar MS; Ramanathan CR; Thirunavukkarasu C Bioorg Med Chem; 2015 Feb; 23(3):488-98. PubMed ID: 25555733 [TBL] [Abstract][Full Text] [Related]
10. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking. Zeng H; Zhang H; Jang F; Zhao L; Zhang J Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709 [TBL] [Abstract][Full Text] [Related]
12. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382 [TBL] [Abstract][Full Text] [Related]
13. Probing PARP1-inhibitor complexes for the development of novel inhibitors. Saqib U; Baig MS Cell Mol Biol (Noisy-le-grand); 2014 Oct; 60(3):43-52. PubMed ID: 25346248 [TBL] [Abstract][Full Text] [Related]
14. In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells. Le TV; Suh JH; Kim N; Park HJ Bioorg Med Chem Lett; 2013 May; 23(9):2642-6. PubMed ID: 23522835 [TBL] [Abstract][Full Text] [Related]
15. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies. Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035 [TBL] [Abstract][Full Text] [Related]
16. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176 [TBL] [Abstract][Full Text] [Related]
17. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity. Wang Z; Qian H; Yiu SM; Sun J; Zhu G J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912 [TBL] [Abstract][Full Text] [Related]
18. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors. Chadha N; Jaggi AS; Silakari O Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128 [TBL] [Abstract][Full Text] [Related]
20. [Construction of pharmacophore model of PARP-1 inhibitor]. Zhang WT; Yan H; Jiang FC Yao Xue Xue Bao; 2007 Mar; 42(3):279-85. PubMed ID: 17520827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]